bluebird bio Announces September Investor Events
05 Settembre 2023 - 10:05PM
Business Wire
bluebird bio, Inc. (Nasdaq: BLUE) today announced that
members of the management team will participate in fireside chats
at the following upcoming investor conferences:
- Morgan Stanley 21st Annual Global Healthcare Conference,
Monday, September 11, at 12:15 p.m. ET at the Sheraton, New York,
NY
- Baird 2023 Global Healthcare Conference, Tuesday, September 12,
at 2:00 p.m. ET at the Intercontinental New York Barclay, New York,
NY
To access the live webcast of bluebird bio’s fireside chats,
please visit the “Events & Presentations” page within the
Investors & Media section of the bluebird bio website at
http://investor.bluebirdbio.com. Replays of the webcasts
will be available on the bluebird bio website for 90 days following
the events.
About bluebird bio, Inc.
bluebird bio is pursuing curative gene therapies to give
patients and their families more bluebird days.
With a dedicated focus on severe genetic diseases, bluebird has
industry-leading programs for sickle cell disease, β-thalassemia
and cerebral adrenoleukodystrophy and is advancing research to
apply new technologies to these and other diseases. We custom
design each of our therapies to address the underlying cause of
disease and have developed in-depth and effective analytical
methods to understand the safety of our lentiviral vector
technologies and drive the field of gene therapy forward.
Founded in 2010, bluebird has the largest and deepest ex-vivo
gene therapy data set in the world—setting the standard for the
industry. Today, bluebird continues to forge new paths, combining
our real-world experience with a deep commitment to patient
communities and a people-centric culture that attracts and grows a
diverse flock of dedicated birds.
For more information, visit bluebirdbio.com or follow us
on social media at @bluebirdbio, LinkedIn,
Instagram and YouTube.
bluebird bio is a trademark of bluebird bio, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230905255288/en/
Investors: Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com
Media: Jess Rowlands, 857-299-6103
jess.rowlands@bluebirdbio.com
Grafico Azioni bluebird bio (NASDAQ:BLUE)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni bluebird bio (NASDAQ:BLUE)
Storico
Da Apr 2023 a Apr 2024